



(51) International Patent Classification:

A61K 9/50 (2006.01) A61K 31/519 (2006.01)

A61K 47/36 (2006.01) A61P 13/12 (2006.01)

A61K 31/44 (2006.01) A61K 31/4418 (2006.01)

(21) International Application Number:

PCT/EP2020/069941

(22) International Filing Date:

15 July 2020 (15.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/874,691 16 July 2019 (16.07.2019) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Södertälje (SE).

(72) Inventors: VON CORSWANT, Christian; AstraZeneca AB, SE-151 85 Södertälje (SE). MALEKI, Laleh; AstraZeneca AB, SE-151 85 Södertälje (SE).

(74) Agent: HOPKIN, Mark, David; AstraZeneca Intellectual Property Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

- with international search report (Art. 21(3))

(54) Title: DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD

(57) Abstract: Disclosed herein are pharmaceutical formulations comprising verinurad or a pharmaceutically acceptable salt thereof that are resistant to alcohol-induced dose dumping and may be used in therapeutic and/or prophylactic methods.

